MHC Class I Antigens In Malignant Cells
Springer-Verlag New York Inc.
978-1-4614-6542-3 (ISBN)
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.
Teresa Cabrera Castillo, Ph.D., MD., is a Full Professor at the Department of Biochemistry, Molecular Biology, and Immunology at the University of Granada and a Medical Immunology Specialist at Hospital Universitario Virgen de las Nieves. Natalia Aptsiauri, Ph.D., MD., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Angel Miguel Garcia Lora, Ph.D., is a Senior Staff Scientist at the Department of Clinical Analysis and Immunology, University Hospital Virgen de las Nieves Please see attached CVs for more detail.
Overview of MHC Class I Antigens.- HLA Class I Expression In Human Cancer.- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns.- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression.- Conclusion.
| Reihe/Serie | SpringerBriefs in Cancer Research ; 1 |
|---|---|
| Zusatzinfo | 14 Illustrations, color; 3 Illustrations, black and white; VIII, 51 p. 17 illus., 14 illus. in color. |
| Verlagsort | New York, NY |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
| Schlagworte | Cancer • immune escape • immunotherapy • Metastasis • MHC class I • tumor rejection |
| ISBN-10 | 1-4614-6542-7 / 1461465427 |
| ISBN-13 | 978-1-4614-6542-3 / 9781461465423 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
